(134 days)
No
The summary describes a mechanical device for thrombus dissolution and does not mention any AI or ML components or functionalities.
Yes
The device is intended for the percutaneous dissolution of acute thrombus, which is a direct treatment for a medical condition (thrombosis), thus classifying it as a therapeutic device.
No
Explanation: The device is intended for the dissolution of thrombus (treatment), not for identifying or diagnosing the presence of thrombus.
No
The device description explicitly states it includes physical components such as a catheter, drive shaft, and a hand-held battery-powered motor drive, indicating it is a hardware device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. They are used to provide information for diagnosis, monitoring, or screening.
- Device Function: The description clearly states that the Micro Therapeutics, Inc. Over the Wire (OTW) Thrombolytic Brush Catheter is a device intended for percutaneous dissolution of acute thrombus located in arteriovenous (A-V) fistula. This is a therapeutic procedure performed within the body, not a test performed on a sample outside the body.
- Mechanism of Action: The device works by physically macerating the clot and augmenting the interface for a pharmacologic agent (like urokinase) to dissolve the thrombus. This is a mechanical and chemical action within the patient's body.
Therefore, this device falls under the category of a therapeutic medical device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Micro Therapeutics, Inc. Over the Wire (OTW) Thrombolytic Brush Catheter is intended for the percutaneous dissolution of acute thrombus located in artificial The OTW Thrombolytic Brush Catheter is designed to arteriovenous (A-V) fistula. augment the area of interface between clot and pharmacologic agent by simultaneous thrombolysis and clot maceration. The integral system utilizes a catheter with proximal Yconnector, a soft brush attached at the distal end of a hollow drive shaft, and a hand-held battery-powered motor drive.
The Micro Therapeutics, Inc. Over the Wire (OTW) Thrombolytic Brush Catheter is intended for percutaneous dissolution of acute thrombus (i.e., less than two weeks old) located in arteriovenous (A-V) fistula utilizing a .035" guide wire for tracking and positioning within the fistula. The OTW Thrombolytic Brush Catheter is designed to augment the area of interface between clot and pharmacologic augment by simultaneous thrombolysis and clot maceration. Clinical studies demonstrate effective dissolution of thrombus in A-V grafts when this product is used in conjunction with urokinase. The OTW Thrombolytic Brush Catheter is not intended for use in native vessels. The device should not be used on patients with a history of significant pulmonary disease or pulmonary hypertension.
Product codes
74 MCW
Device Description
The Micro Therapeutics, Inc. Over the Wire (OTW) Thrombolytic Brush Catheter is intended for the percutaneous dissolution of acute thrombus located in artificial The OTW Thrombolytic Brush Catheter is designed to arteriovenous (A-V) fistula. augment the area of interface between clot and pharmacologic agent by simultaneous thrombolysis and clot maceration. The integral system utilizes a catheter with proximal Yconnector, a soft brush attached at the distal end of a hollow drive shaft, and a hand-held battery-powered motor drive.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Arteriovenous (A-V) fistula
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance Data
In Vitro Tests
Sample sterile devices were subjected to extensive physical bench testing. In vitro tests were conducted which included dimensional measurements, bristle and wire cable strength characterization, motor drive integrity testing, catheter flow rates, bond strengths, burst pressure and performance under simulated conditions. Additionally, electromagnetic and patient safety tests were conducted by an independent laboratory to evaluate the electromagnetic and leakage current potential of the battery operated motor drive handle. Based on the results from these tests, it was concluded that the design performed equivalently to the predicate device and is suitable for its intended use.
In Vivo Tests
In vivo animal tests were performed to assess the performance of the Micro Therapeutics, Inc. Over the Wire (OTW) Thrombolytic Brush Catheter to that of a predicate device. The animal studies demonstrated that the OTW Thrombolytic Brush Catheter performed the same as the predicate device for percutaneous administration of pharmacologicals for dissolution of thrombus located in A-V fistulas.
Biocompatibility Tests
All components tested per ISO 10993-1.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.4875 Intraluminal artery stripper.
(a)
Identification. An intraluminal artery stripper is a device used to perform an endarterectomy (removal of plaque deposits from arterisclerotic arteries.)(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/2 description: The image shows the logo for Micro Therapeutics, Inc. The logo consists of the letters "MTI" in a bold, stylized font, with a series of small squares arranged in a grid pattern to the left of the letters. To the right of the letters is the full name of the company, "MICRO THERAPEUTICS, INC.", in a smaller, but still legible, font.
1062-F Calle Negocio San Clemente, CA 92673 Tel. 714-361- 0616 Fax 714- 361-0210
510(k) SUMMARY
Contact Person
Jack Gehrich Vice President of Regulatory & Clinical Affairs
Trade Name
Over the Wire (OTW) Thrombolytic Brush Catheter
Common Name
Thrombectomy Catheter Infusion Catheter
Classification Name
Percutaneous Catheter (per 21 CFR 870.1250)
Substantially Equivalent Devices
Thrombolytic Brush Catheter (Micro Therapeutics)
Description
The Micro Therapeutics, Inc. Over the Wire (OTW) Thrombolytic Brush Catheter is intended for the percutaneous dissolution of acute thrombus located in artificial The OTW Thrombolytic Brush Catheter is designed to arteriovenous (A-V) fistula. augment the area of interface between clot and pharmacologic agent by simultaneous thrombolysis and clot maceration. The integral system utilizes a catheter with proximal Yconnector, a soft brush attached at the distal end of a hollow drive shaft, and a hand-held battery-powered motor drive.
Intended Use
The Micro Therapeutics, Inc. Over the Wire (OTW) Thrombolytic Brush Catheter is intended for percutaneous dissolution of acute thrombus (i.e., less than two weeks old) located in arteriovenous (A-V) fistula utilizing a .035" guide wire for tracking and positioning within the fistula. The OTW Thrombolytic Brush Catheter is designed to augment the area of interface between clot and pharmacologic augment by simultaneous thrombolysis and clot maceration. Clinical studies demonstrate effective dissolution of thrombus in A-V grafts when this product is used in conjunction with urokinase. The OTW Thrombolytic Brush Catheter is not intended for use in native vessels. The device should not be used on patients with a history of significant pulmonary disease or pulmonary hypertension.
00046
1
510(k) SUMMARY (cont.)
Technological Characteristics
This product is equivalent in intended use, as well as dimensional characteristics, composition and function to the legally marketed Thrombolytic Brush Catheter, (K963925) manufactured by Micro Therapeutics, Inc.
Summary of Studies
Performance Data
In Vitro Tests
Sample sterile devices were subjected to extensive physical bench testing. In vitro tests were conducted which included dimensional measurements, bristle and wire cable strength characterization, motor drive integrity testing, catheter flow rates, bond strengths, burst pressure and performance under simulated conditions. Additionally, electromagnetic and patient safety tests were conducted by an independent laboratory to evaluate the electromagnetic and leakage current potential of the battery operated motor drive handle. Based on the results from these tests, it was concluded that the design performed equivalently to the predicate device and is suitable for its intended use.
In Vivo Tests
In vivo animal tests were performed to assess the performance of the Micro Therapeutics, Inc. Over the Wire (OTW) Thrombolytic Brush Catheter to that of a predicate device. The animal studies demonstrated that the OTW Thrombolytic Brush Catheter performed the same as the predicate device for percutaneous administration of pharmacologicals for dissolution of thrombus located in A-V fistulas.
Biocompatibility Tests
All components tested per ISO 10993-1.
Conclusion: The Micro Therapeutics, Inc. Over the Wire (OTW) Thrombolytic Brush Catheter is substantially equivalent to the predicate device based on the results of laboratory and animal testing.
00047
2
Image /page/2/Picture/2 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized eagle with its wings spread, symbolizing protection and service. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" are arranged in a circular pattern around the eagle. The seal is simple and monochromatic.
Rockville MD 20857
FEB - 6 1998
Mr. Brian Strauss Project Engineer Micro Therapeutics, Inc. 1062-F Calle Negocio San Clemente, CA 92673
K973669 Re: Over-the-Wire (OTW) Thrombolytic Brush Catheter Regulatory Class: II (two) Product Code: 74 MCW Dated: January 7, 1998 Received: January 9, 1998
Dear Mr. Strauss:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 A substantially equivalent determination assumes compliance to 895. with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS-inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in requlatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Number: K973669
Device Name:
Micro Therapeutics Over the Wire (OTW) Thrombolytic Brush Catheter
Indications for Use:
The Micro Therapeutics, Inc. Over the Wire (OTW) Thrombolytic Brush Catheter is intended for percutaneous dissolution of acute thrombus located in arteriovenous (A-V) fistula. The Over the Wire (OTW) Thrombolytic Brush Catheter is designed to augment the area of interface between clot and pharmacologic augment by simultaneous thrombolysis and clot maceration. Clinical studies demonstrate effective dissolution of thrombus in A-V grafts when this product is used in conjunction with urokinase. The Over the Wire (OTW) Thrombolytic Brush Catheter is not intended for use in native vessels. The device should not be used on patients with a history of significant pulmonary disease of pulmonary hypertension.
If Micro Therapeutics, Inc. intends to recommend its Over the Wire (OTW) Thrombolytic Brush Catheter interface with specific pharmacological agents, Micro Micro Therapeutics will notify the Food and Drug Administration. Therapeutics, Inc. will not promote any such action until the Food and Drug Administration has reviewed and approved such action.
Administration has re
Th of th
(Division Sign-Off) Division of Cardiovascular. Respiratory. and Neurological Devic 510(k) Number _
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
✓
OR
Over the Counter Use
000491